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Testing for the DNA of high-risk types of papilloma virus (HPV) is more sensitive than cytology in
detecting pre-cancerous lesions. One of the main advantages will be the possibility of applying
prolonged screening intervals. However adequate screening protocols (age of start and stop,
screening intervals, management of HPV positive women) need to be applied in order to avoid
over-referral to colposcopy and over-treatment and to maintain sustainable costs. Further follow-
up of running trials and research on molecular markers will better define these parameters. The
new situation will require organised screening programmes with rigorous protocols and
monitoring. This will be even more needed when women vaccinated for HPV 16 and 18 will be
screened. Research on how to best screen vaccinated women is a priority. This paper proposes an
overview of the plausible impact of new technologies in cervical cancer screening in the near future
and in the vaccinated cohorts.
Background
Human Papilloma virus (HPV) as primary screening test of 
cervical cancer precursors
Both studies based on double-testing of the same women
[1,2] and large population trials [3-8] showed that testing
for the DNA of high-risk HPV types is more sensitive but
less specific than conventional cytology in identifying
high-grade cervical intraepithelial neoplasia (CIN).
HPV testing detects almost all high-grade CINs identified
by cytology [1,2]. As a result, almost the same sensitivity
is obtained with HPV alone as with both cytology and
HPV together as primary screening tests (i.e. if only HPV-
positive or also HPV-negative women with abnormal
cytology are referred to colposcopy). However, with the
combined strategy, referrals to colposcopy are much more
frequent and the probability that test-positive women
actually have a high-grade CIN (the Positive Predictive
Value, PPV) is substantially lower [3,4].
In women at least 35 years of age, in the "New Technology
in Cervical Cancer" (NTCC) trial, HPV testing was found
to be 63% more sensitive than cytology when all HPV-
positive women are referred to colposcopy [8]. At this age
loss in specificity is small: in a pooled analysis of Euro-
pean and North American studies based on double-testing
[1], specificity was 93.3% with HPV DNA testing vs.
97.1% with cytology. However, even with HPV alone
there is a remarkable loss in PPV. In the NTCC trial the rel-
ative ratio in PPV between HPV and cytology (relative
PPV) was 0.67 [8].
Thus, a number of strategies to increase specificity have
been or are being evaluated. The most studied strategy –
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that we will refer to as "cytological triage" – involves
directly referring to colposcopy only HPV-positive women
who also show cytological abnormalities, while the
remaining HPV-positives are retested at shorter interval
and referred to colposcopy only if they retest as HPV pos-
itive [9]. This approach is based on knowledge that only
persistent HPV infections are relevant to carcinogenesis.
Trials based on combined HPV and cytology screening but
with cytological triage of HPV-positive women at least 30
(POBASCAM [6]) or 35 (Sweedscreen [7]) years of age
found sensitivities about 50% higher than with cytology
alone, very similar to those obtained when all HPV posi-
tive women are referred.
The persistence of lesions detected by HPV testing versus
cytology is also a relevant factor. Remarkably, the two
aforementioned studies [6,7] showed that HPV testing
allowed an earlier detection of persistent, therefore clini-
cally relevant, lesions. It is plausible that both age and the
application of triage had a role in such a result. The
observed earlier diagnosis means that the intervals for re-
screening HPV-negative women can be longer. The very
low detection rate of high-grade CIN at subsequent
screening in previously HPV-negative women supports
this choice. Longer intervals have the clear advantage of
fewer screening episodes over a lifetime and may provide
the opportunity of achieving higher coverage. Further fol-
low-up of randomised trials will provide evidence on how
long HPV screening intervals can be [10].
However, cytological triage requires that some women are
re-tested at short intervals, which is a disadvantage
because compliance rarely is complete. Other strategies,
based on molecular markers, are under study. These
include viral load, genotyping, testing for the RNA of the
viral oncogenes E6 and E7 and testing for the over-expres-
sion of the p16-INK4A protein [11]. Recently HPV testing
with a single immediate triage test for p16-INK4A over-
expression – with no further recall – showed a relative sen-
sitivity of 1.53 with virtually no increase in referrals to col-
poscopy (relative referral 1.08) [12].
Among younger women the situation is slightly more
complicated. At this age infection is very frequent and
HPV test specificity is lower. Nevertheless, among women
25–34 years of age, in the NTCC trial, HPV testing with
cytological triage resulted in a relative sensitivity vs. cytol-
ogy of 1.58 with only a moderate loss in PPV (relative PPV
0.78) [4]. However, a major problem at this age is over-
diagnosis. Data from the NTCC study, involving direct
referral of all HPV positive women, found a very large
increase in sensitivity (relative sensitivity 3.50) suggesting
that a large proportion of the lesions detected by this strat-
egy at this age are regressive. Results from the follow-up of
the NTCC study, currently under analysis, will provide
information on the appropriateness of HPV screening at
younger ages.
Conclusion
In conclusion, available results strongly support the adop-
tion of HPV testing for cervical screening. However, before
general routine implementation, the follow-up results of
running randomised trials, which will be available soon,
should be considered. They will also provide evidence on
some aspects that need to be better defined: age at first
testing, the best screening interval, the best management
of HPV positive women. In the meantime, starting large
pilot (demonstration) projects seems reasonable. This
will allow us to estimate the impact of the application of
new technologies in practice, evaluate costs (to date the
major barrier to using HPV as the primary test is the price
of the kit [13]) and set up systems for quality assurance
and monitoring.
In any case, the following issues must be taken into
account:
- Applying longer screening intervals represents a major
advantage of HPV testing. This is also needed in order to
maintain sustainable costs.
- Adequate protocols need to be applied. In their absence
there is a risk not only of over-referral to colposcopy but
also of overtreatment (see the case of direct referral to col-
poscopy of younger HPV positive women), and therefore
for potential harm (excisional treatment for CIN increases
the risk of complications in pregnancy [14,15]).
- Validated tests with appropriate sensitivity and more
importantly, specificity must be adopted
All of these factors indicate the need for organised screen-
ing programmes that actively invite women at the appro-
priate intervals, adopt well-defined management
protocols, register all results (the application of protocols
requires accurate knowledge of women's screening experi-
ence) and monitor performances.
New scenario in the vaccine era
Two vaccines – one against the oncogenic HPV types 16
and 18 and one that also includes the non-oncogenic
types 6 and 11 – proved to be highly effective in prevent-
ing HPV16/18-linked CIN2+ [16,17]. In some countries
vaccination is free of charge or actively offered to adoles-
cents [18]. There is large consensus that vaccinated
women need screening [19-21], as HPV 16 and 18 are
only responsible for 75% of cervical cancers. We must
understand how vaccinated women should best be
screened. In vaccinated women the incidence of CIN2+ is
expected to be reduced by 50–60% compared to theBMC Women's Health 2008, 8:23 http://www.biomedcentral.com/1472-6874/8/23
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unvaccinated but vaccination reduces the incidence of low
grade CIN and ASC-US only by 20% [22]. Thus, with
cytology, the detection rate will decrease much more than
referrals to colposcopy. Consequently PPV will substan-
tially decrease. However, as non-16/18 HPV types have a
lower probability of neoplastic progression, the PPV of
HPV testing will also decrease in vaccinated women.
Overall, this scenario represents an additional reason for
shifting to HPV testing but will require even more con-
servative protocols, to achieve high PPV for colposcopy
referral, both in order to avoid false positive histological
diagnoses (that are inversely related to the PPV of referral
[23]) and to maintain sustainable overall costs of cervical
cancer control. The lower incidence of high-grade CIN
with non-16/18 HPV types [24] – therefore the longer
interval between infection and the development of such
lesions – suggests the possibility of even longer screening
intervals. Research on this subject is a priority. In any case,
this situation will need a coordinated program for cervical
cancer prevention that will be able to integrate vaccina-
tions and screening, ensuring appropriate prevention to
all women throughout their life, according to their history
of immunisation and screening.
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